Caution - Investigational Drug; Limited by United States Law to Investigational use only.
Caution - Investigational Drug; Limited by United States Law to Investigational use only.
Mission and Strategy

Mission and Strategy

Success through development of breakthrough therapies.

Our mission: Introducing the first therapy with proven outcome benefits for patients with acute heart failure

Heart failure management represents one of the major challenges in medicine and health care today. Heart failure affects up to 4% of the adult population and up to 20% of the rapidly increasing population >65 years of age. To improve outcomes for people with heart failure and shape the future of patient care.

Our strategy: Developing innovative medicines for diseases of high unmet medical need

Focused, fast moving and flexible, with patients at its heart, Cardiorentis AG is committed to bringing novel therapies to the treatment of heart failure and related cardiovascular diseases. We aim to do this by:

Focusing on acute cardiovascular indications and their long-term treatment

Focusing on acute cardiovascular indications and their long-term treatment

Developing the first therapie with proven outcome benefits for patients with acute heart failure

Developing the first therapy with proven outcome benefits for patients with acute heart failure

 
Growing our partnerships with academic researchers, universities and practicing clinicians across the world to help drive important cardiovascular research and clinical trials forward

Growing our partnerships with academic researchers, universities and practicing clinicians across the world to help drive important cardiovascular research and clinical trials forward

Making a difference in life threatening diseases

Making a difference in life threatening diseases

 
Mission and Strategy